Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk

Section Structure

Highlights

Biomarker-driven prognostic models originally developed in EMPEROR-Preserved performed well when externally applied to FINEARTS-HF, supporting their broader transportability in patients with heart failure with mildly reduced or preserved ejection fraction.